2008 Alzheimer’s Disease Summit CME Information

THE ALZHEIMER’S DISEASE SUMMIT provided a comprehensive update of recent advances in AD diagnosis and management. Leading experts Jeffrey L. Cummings, MD, and Pierre N. Tariot, MD, assembled a faculty of key opinion leaders who gave brief lectures and provided question-and-answer opportunities for dialogue with participants. Russell Katz, MD, Director of Neurology Products, United States Food and Drug Administration, provided an update on topics relevant to drug development as part of a concluding expert panel discussion.

Program Goal
The Summit will translate cutting-edge research into impactful knowledge applicable to the daily practices of an audience of 300 neurologists, psychiatrists, and primary care physicians.

Program Objectives
Upon completion of the activity, participants will be able to

1. Apply new clinical assessment techniques in their practice.
2. Distinguish when to use a specific type of imaging to assist in the diagnosis of AD.
3. Assess current available medications for the optimal management of AD.
4. Discuss treatment research related to amyloid-based therapies and neuroprotection.

Target Audience
Neurologists, Psychiatrists, and Primary Care Physicians

Accreditation
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Mount Sinai School of Medicine designated this educational activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Verification of Attendance
Was provided to all professionals.

Acknowledgment of Commercial Support
This activity was supported in part by educational grants from Forest Laboratories, Inc., Eisai Inc., Medivation, Inc., and Elan Pharmaceuticals, Inc.

Special Needs
If you would like to attend this conference and require any special needs or accommodations, please contact Kimberly Schneider at 212-328-0800.

Registration Information

Summit Location
All sessions were held at the Park Hyatt in Washington DC.
Hotel Information
Transportation
Attractions

Summit Information
Please visit www.alzsummit.com or call Kimberly Schneider at 212-328-0800 or via email at ks@mblcommunications.com.

Program Agenda

Faculty Chairs and Presenters

Program Chairs:

Jeffrey L. Cummings, MD: Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Science
Director, UCLA Alzheimer’s Disease Center
Director, Deane F. Johnson Center for Neurotherapeutics
David Geffen School of Medicine at University of California at Los Angeles

Pierre N. Tariot, MD
Research Professor of Psychiatry
University of Arizona College of Medicine
Director, Memory Disorders Center
Banner Alzheimer’s Institute

CME Course Director:

Eric Hollander, MD
Chair and Professor of Psychiatry
Mount Sinai School of Medicine

Faculty:

Paul S. Aisen, MD
Director of the Alzheimer’s Disease Cooperative Study
University of California at San Diego

Liana Apostolova, MD
Assistant Professor, UCLA Alzheimer’s Disease Center
University of California at Los Angeles

Rachelle Doody, MD, PhD
Chair in Alzheimer’s Disease Research
Director, Alzheimer’s Disease and Memory Disorders Center
Professor of Neurology
Baylor College of Medicine

Russell Katz, MD
Director, Neurology Products
Food and Drug Administration

Mark A. Mintun, MD
Professor of Radiology, of Psychiatry, and of Biomedical Engineering
Director, Center for Clinical Imaging Research
Director, Division of Research Development
Washington University School of Medicine

Ziad Nasreddine, MD
Neurologist, Neuro-Rive-Sud Memory Clinic
Director, Neuro-Rive-Sud Memory Clinic
Assistant Clinical Professor
University of Sherbrooke and McGill University

Elaine Peskind, MD
Associate Director, Alzheimer’s Disease Research Center
University of Washington Medical Center

Norman Relkin, PhD, MD
Director, Cornell Memory Disorders Program
Weill Cornell Medical College

Mary Sano, PhD
Professor of Psychiatry
Director, Alzheimer’s Disease Research Center
Mount Sinai School of Medicine

Gary W. Small, MD
Director, UCLA Center on Aging
Professor of Psychiatry and Biobehavioral Sciences
University of California at Los Angeles

Kathleen Welsh-Bohmer, PhD
Director, Bryan Alzheimer’s Disease Research Center
Duke University of Medicine

Faculty Disclosure Policy
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.